{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:35:07Z","timestamp":1785497707684,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains a common and difficult cancer to treat. Surgical resection and chemotherapy are standard of care and clinical outcomes remain poor. Oncolytic adenoviruses are a unique approach to the treatment of this challenging cancer, aiming to overcome the features of this disease that pose the key obstacles to standard therapies. This paper provides a detailed review of the clinical trials of conditionally-replicative adenoviruses in pancreatic cancer to date, with a brief summary of the past preclinical literature and future prospects of this therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MEDLINE, Embase, and clinicaltrials.gov were searched from inception to December 23rd 2022 for clinical trials of conditionally-replicative adenoviruses used in patients with pancreatic ductal adenocarcinoma. Primary features for review included patient demographics, treatment protocol including dose and administration route, adverse events, patient responses and survival rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The six published clinical trials suggest that objective clinical responses can be achieved with a tolerable level of side effects, even at high viral doses. The more clinically adaptable intravenous route of administration also appears to be as well tolerated as the more challenging intratumoural injections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Published clinical trials provide data of the safety and some signs of oncolytic activity of conditionally-replicative adenoviruses in patients with pancreatic cancer. Importantly, on the latest trials, the easier intravenous route of administration seems to be well tolerated and safe, providing the opportunity for further clinical evaluation. It is hoped that the ongoing clinical trials will yield more promising results of this therapeutic approach against a currently intractable disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-04735-w","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T18:02:15Z","timestamp":1680976935000},"page":"8117-8129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-7759","authenticated-orcid":false,"given":"Isobel P.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9370-1516","authenticated-orcid":false,"given":"J. Alejandro","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,8]]},"reference":[{"key":"4735_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.omto.2020.11.006","volume":"20","author":"KN Barton","year":"2021","unstructured":"Barton KN, Siddiqui F, Pompa R, Freytag SO, Khan G, Dobrosotskaya I, Ajlouni M, Zhang Y, Cheng J, Movsas B, Kwon D (2021) Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Mol Ther Oncolytics 20:94\u2013104. https:\/\/doi.org\/10.1016\/j.omto.2020.11.006","journal-title":"Mol Ther Oncolytics"},{"key":"4735_CR2","doi-asserted-by":"publisher","unstructured":"Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, Alvarez R, Mato-Berciano A, Gimenez-Alejandre M, Morgado S, Rodriguez-Garcia A, Maliandi MV, Riesco MC, Moreno R, Ginesta MM, Perez-Carreras M, Gornals JB, Prados S, Perea S, Capella G, Alemany R, Salazar R, Hidalgo M (2021) VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003254","DOI":"10.1136\/jitc-2021-003254"},{"issue":"5286","key":"4735_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274(5286):373\u2013376. https:\/\/doi.org\/10.1126\/science.274.5286.373","journal-title":"Science"},{"issue":"12","key":"4735_CR4","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1089\/hum.2012.043","volume":"23","author":"M Bunuales","year":"2012","unstructured":"Bunuales M, Garcia-Aragoncillo E, Casado R, Quetglas JI, Hervas-Stubbs S, Bortolanza S, Benavides-Vallve C, Ortiz-de-Solorzano C, Prieto J, Hernandez-Alcoceba R (2012) Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer. Hum Gene Ther 23(12):1258\u20131268. https:\/\/doi.org\/10.1089\/hum.2012.043","journal-title":"Hum Gene Ther"},{"key":"4735_CR5","doi-asserted-by":"publisher","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Intergroup P (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","DOI":"10.1056\/NEJMoa1011923"},{"key":"4735_CR6","doi-asserted-by":"publisher","unstructured":"Du YN, Wei Q, Zhao LJ, Fan CQ, Guo LR, Ye JF, Li Y (2022) Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy. Biomed Pharmacother 151:113110. https:\/\/doi.org\/10.1016\/j.biopha.2022.113110","DOI":"10.1016\/j.biopha.2022.113110"},{"key":"4735_CR7","doi-asserted-by":"publisher","unstructured":"Garcia-Carbonero R, Bazan-Peregrino M, Gil-Martin M, Alvarez R, Macarulla T, Riesco-Martinez MC, Verdaguer H, Guillen-Ponce C, Farrera-Sal M, Moreno R, Mato-Berciano A, Maliandi MV, Torres-Manjon S, Costa M, Del Pozo N, Martinez de Villarreal J, Real FX, Vidal N, Capella G, Salazar R (2022) Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003255","DOI":"10.1136\/jitc-2021-003255"},{"key":"4735_CR8","doi-asserted-by":"publisher","unstructured":"Hamidi-Sofiani V, Rakhshi R, Moradi N, Zeynali P, Nakhaie M, Behboudi E (2022) Oncolytic viruses and pancreatic cancer. Cancer Treat Res Commun 31:100563. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100563","DOI":"10.1016\/j.ctarc.2022.100563"},{"issue":"4","key":"4735_CR9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/ijc.29442","volume":"137","author":"K Hammer","year":"2015","unstructured":"Hammer K, Kazcorowski A, Liu L, Behr M, Schemmer P, Herr I, Nettelbeck DM (2015) Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. Int J Cancer 137(4):978\u2013990. https:\/\/doi.org\/10.1002\/ijc.29442","journal-title":"Int J Cancer"},{"key":"4735_CR10","unstructured":"Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM (2003) A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 9(2):555\u2013561. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12576418"},{"issue":"6","key":"4735_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nm0697-639","volume":"3","author":"C Heise","year":"1997","unstructured":"Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3(6):639\u2013645. https:\/\/doi.org\/10.1038\/nm0697-639","journal-title":"Nat Med"},{"key":"4735_CR12","doi-asserted-by":"publisher","unstructured":"Kaczorowski A, Hammer K, Liu L, Villhauer S, Nwaeburu C, Fan P, Zhao Z, Gladkich J, Gross W, Nettelbeck DM, Herr I (2016) Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells. Oncotarget 7(8):9046\u20139059. https:\/\/doi.org\/10.18632\/oncotarget.7031","DOI":"10.18632\/oncotarget.7031"},{"key":"4735_CR13","doi-asserted-by":"publisher","unstructured":"Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E, Alliance for Clinical Trials on O (2017) Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer 17(1):505. https:\/\/doi.org\/10.1186\/s12885-017-3441-z","DOI":"10.1186\/s12885-017-3441-z"},{"key":"4735_CR14","doi-asserted-by":"publisher","unstructured":"Lee JC, Shin DW, Park H, Kim J, Youn Y, Kim JH, Kim J, Hwang JH (2020) Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. Gastrointest Endosc 92(5):1044\u20131052 e1041. https:\/\/doi.org\/10.1016\/j.gie.2020.02.012","DOI":"10.1016\/j.gie.2020.02.012"},{"issue":"31","key":"4735_CR15","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","volume":"29","author":"PJ Loehrer Sr","year":"2011","unstructured":"Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29(31):4105\u20134112. https:\/\/doi.org\/10.1200\/JCO.2011.34.8904","journal-title":"J Clin Oncol"},{"key":"4735_CR16","doi-asserted-by":"publisher","unstructured":"Man YKS, Aguirre-Hernandez C, Fernandez A, Martin-Duque P, Gonzalez-Pastor R, Hallden G (2022) Complexing the oncolytic adenoviruses Ad and Ad-3-A20T with cationic nanoparticles enhances viral infection and spread in prostate and pancreatic cancer models. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23168884","DOI":"10.3390\/ijms23168884"},{"issue":"4","key":"4735_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/sj.gt.3301398","volume":"8","author":"S Mulvihill","year":"2001","unstructured":"Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D (2001) Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 8(4):308\u2013315. https:\/\/doi.org\/10.1038\/sj.gt.3301398","journal-title":"Gene Ther"},{"issue":"Pt B","key":"4735_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jconrel.2015.10.015","volume":"220","author":"Y Na","year":"2015","unstructured":"Na Y, Choi JW, Kasala D, Hong J, Oh E, Li Y, Jung SJ, Kim SW, Yun CO (2015) Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model. J Control Release 220(Pt B):766\u2013782. https:\/\/doi.org\/10.1016\/j.jconrel.2015.10.015","journal-title":"J Control Release"},{"key":"4735_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2019.04.040","volume":"305","author":"Y Na","year":"2019","unstructured":"Na Y, Nam JP, Hong J, Oh E, Shin HC, Kim HS, Kim SW, Yun CO (2019) Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration. J Control Rel 305:75\u201388. https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.040","journal-title":"J Control Rel"},{"key":"4735_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2018.07.006","volume":"434","author":"CB Nattress","year":"2018","unstructured":"Nattress CB, Hallden G (2018) Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Lett 434:56\u201369. https:\/\/doi.org\/10.1016\/j.canlet.2018.07.006","journal-title":"Cancer Lett"},{"key":"4735_CR21","doi-asserted-by":"publisher","unstructured":"Nishimae F, Sakurai F, Ono R, Onishi R, Takayama K, Mizuguchi H (2022) A dopamine antagonist, domperidone enhances the replication of an oncolytic adenovirus in human tumour cells. J Gen Virol. https:\/\/doi.org\/10.1099\/jgv.0.001752","DOI":"10.1099\/jgv.0.001752"},{"issue":"10","key":"4735_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jjco\/hyg093","volume":"33","author":"JO Park","year":"2003","unstructured":"Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K (2003) Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 33(10):533\u2013537. https:\/\/doi.org\/10.1093\/jjco\/hyg093","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"4735_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM (2021) Pancreatic cancer: a review. JAMA 326(9):851\u2013862. https:\/\/doi.org\/10.1001\/jama.2021.13027","journal-title":"JAMA"},{"key":"4735_CR24","doi-asserted-by":"publisher","unstructured":"Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A (2021) The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy. Front Oncol 11:688377. https:\/\/doi.org\/10.3389\/fonc.2021.688377","DOI":"10.3389\/fonc.2021.688377"},{"key":"4735_CR25","doi-asserted-by":"publisher","unstructured":"Santos J, Heinio C, Quixabeira D, Zafar S, Clubb J, Pakola S, Cervera-Carrascon V, Havunen R, Kanerva A, Hemminki A (2021) Systemic delivery of oncolytic adenovirus to tumors using tumor-infiltrating lymphocytes as carriers. Cells. https:\/\/doi.org\/10.3390\/cells10050978","DOI":"10.3390\/cells10050978"},{"issue":"2","key":"4735_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/1568009617666170222123925","volume":"18","author":"M Sato-Dahlman","year":"2018","unstructured":"Sato-Dahlman M, Yamamoto M (2018) The development of oncolytic adenovirus therapy in the past and future\u2014for the case of pancreatic cancer. Curr Cancer Drug Targets 18(2):153\u2013161. https:\/\/doi.org\/10.2174\/1568009617666170222123925","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"4735_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4735_CR28","doi-asserted-by":"publisher","unstructured":"Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, de Vries JJJ, van den Tol MP, Bruynzeel AME, Streppel MM, Wilmink JW, van der Vliet HJ, Meijerink MR, Scheffer HJ, de Gruijl TD (2021) Pancreatic cancer and immunotherapy: a clinical overview. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13164138","DOI":"10.3390\/cancers13164138"},{"key":"4735_CR29","doi-asserted-by":"publisher","unstructured":"Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Investigators H (2020) Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol 38(27):3185\u20133194. https:\/\/doi.org\/10.1200\/JCO.20.00590","DOI":"10.1200\/JCO.20.00590"},{"key":"4735_CR30","doi-asserted-by":"publisher","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","DOI":"10.1056\/NEJMoa1304369"},{"key":"4735_CR31","doi-asserted-by":"publisher","unstructured":"Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens F, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Dutch Pancreatic Cancer G (2020) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol 38(16):1763\u20131773. https:\/\/doi.org\/10.1200\/JCO.19.02274","DOI":"10.1200\/JCO.19.02274"},{"key":"4735_CR32","unstructured":"Welfare AIOHA (2022) Cancer data in Australia. Australian Institute of Health and Welfare. Retrieved Oct 31, from https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia"},{"issue":"3","key":"4735_CR33","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1021\/mp4005854","volume":"11","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Goto N, Miura K, Narumi K, Ohnami S, Uchida H, Miura Y, Yamamoto M, Aoki K (2014) Development of a novel efficient method to construct an adenovirus library displaying random peptides on the fiber knob. Mol Pharm 11(3):1069\u20131074. https:\/\/doi.org\/10.1021\/mp4005854","journal-title":"Mol Pharm"},{"key":"4735_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-022-00741-1","author":"Y-H Zhu","year":"2022","unstructured":"Zhu Y-H, Zheng J-H, Jia Q-Y, Duan Z-H, Yao H-F, Yang J, Sun Y-W, Jiang S-H, Liu D-J, Huo Y-M (2022) Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Cell Oncol. https:\/\/doi.org\/10.1007\/s13402-022-00741-1","journal-title":"Cell Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04735-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04735-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04735-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T17:47:28Z","timestamp":1690480048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04735-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,8]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4735"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04735-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,8]]},"assertion":[{"value":"9 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}